|March 7, 2017|
|Verastem to Present at the 29th Annual ROTH Conference|
BOSTON--(BUSINESS WIRE)--Mar. 7, 2017--
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing
drugs to treat cancer, today announced that the company will present at
the 29th Annual ROTH Conference on Monday, March 13th
at 4:00 p.m. PT at the Ritz Carlton in Dana Point, CA.
A live audio webcast of the presentation will be available on the
company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has
successfully met its primary endpoint in a Phase 2 study and is
currently being evaluated in a Phase 3 clinical trial in patients with
chronic lymphocytic leukemia (CLL). Other clinical product candidates
include focal adhesion kinase (FAK) inhibitors defactinib and VS-4718,
and dual PI3K/mTOR inhibitor VS-5584. Defactinib is currently being
evaluated in three separate clinical collaborations in combination with
immunotherapeutic agents for the treatment of several different cancer
types, including pancreatic, ovarian and non-small cell lung cancer, and
mesothelioma. Verastem’s product candidates seek to treat cancer by
modulating the local tumor microenvironment, enhancing anti-tumor
immunity and reducing cancer stem cells. For more information, please
View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005389/en/
Source: Verastem, Inc.
Brian Sullivan, 781-292-4214